Diffuse Glioma

Taylor, et al. (2014) presented 26 diffuse midline glioma, H3 K27M-mutant (here referred to as diffuse intrinsic pontine glioma) cases (median age 6 years, median overall survival was 11 months). Whol… (full text at CIViC)

PMID 24705252 · Taylor et al., 2014 · Open in CIViC

Taylor, et al. (2014) presented 26 diffuse midline glioma, H3 K27M-mutant (here referred to as diffuse intrinsic pontine glioma) cases (median age 6 years, median overall survival was 11 months, 20 of… (full text at CIViC)

PMID 24705252 · Taylor et al., 2014 · Open in CIViC

Taylor, et al. (2014) presented 26 diffuse midline glioma, H3 K27M-mutant (here referred to as diffuse intrinsic pontine glioma) cases (median age 6 years, median overall survival was 11 months, 20 of… (full text at CIViC)

PMID 24705252 · Taylor et al., 2014 · Open in CIViC

Zhang et al. (2013) studied 151 tumors from 149 patients. The H3F3A p.K27M variant has been reported in 3 tumors (1.9%). The first sample (SJLGG037_D) was of a less than 3-year-old male patient screen… (full text at CIViC)

PMID 23583981 · Zhang et al., 2013 · Open in CIViC

Buczkowicz, et al. (2014) analyzed 74 diffuse midline glioma, H3 K27M-mutant (here referred to as diffuse intrinsic pontine glioma) cases (median age at diagnosis 6 years, median survival of 10 months… (full text at CIViC)

PMID 24705254 · Buczkowicz et al., 2014 · Open in CIViC

Buczkowicz, et al. (2014) analyzed 74 diffuse midline glioma, H3 K27M-mutant (here referred to as diffuse intrinsic pontine glioma) cases (median age at diagnosis 6 years, median survival of 10 months… (full text at CIViC)

PMID 24705254 · Buczkowicz et al., 2014 · Open in CIViC

Kleinschmidt-DeMasters, et al. (2018) analyzed the tumor database for patients with the H3 K27M variant and found 28 cases (including 3 meeting WHO grade I and 25 meeting WHO grade II-IV criteria). Th… (full text at CIViC)

PMID 29393845 · Kleinschmidt-DeMasters et al., 2018 · Open in CIViC

Kleinschmidt-DeMasters, et al. (2018) analyzed the tumor database for patients with the H3 K27M variant and found 28 cases (including 3 meeting WHO grade I and 25 meeting WHO grade II-IV criteria). Th… (full text at CIViC)

PMID 29393845 · Kleinschmidt-DeMasters et al., 2018 · Open in CIViC

Yoshimoto, et al. (2017) analyzed 411 gliomas of Japanese patients (median age of 46 years (ranged between 1 to 87 years)). Direct sequencing revealed H3F3A p.K27R in one 51 years of age oligodendrogl… (full text at CIViC)

PMID 28447171 · Yoshimoto et al., 2017 · Open in CIViC

Diffuse intrinsic pontine glioma (DIPG) patients harboring a H3.3 K27M mutation have a proneural/oligodendroglial phenotype and a prometastatic gene expression with PDGFRA activation. These mutation c… (full text at CIViC)

PMID 26399631 · Castel et al., 2015 · Open in CIViC

In a pooled analysis of five phase I–II trials and an expanded access program of ONC201 (dordaviprone) for recurrent H3 K27M–mutant diffuse midline glioma (NCT02525692, NCT03295396, NCT03416530, NCT03… (full text at CIViC)

PMID 38335473 · Arrillaga-Romany et al., 2024 · Open in CIViC

In a phase 2 trial, patients with H3 K27M mutant glioma have been treated with DRD2 antagonist ONC201. Among 29 patients, 1 patient experienced complete clinical regression lasting >14 months, and 3 p… (full text at CIViC)

Open in CIViC

Yoshimoto, et al. (2017) analyzed 411 gliomas of Japanese patients (median age of 46 years (ranged between 1 to 87 years)). Direct sequencing revealed H3F3A p.K27R in one 37 years of age anaplastic as… (full text at CIViC)

PMID 28447171 · Yoshimoto et al., 2017 · Open in CIViC

Yoshimoto, et al. (2017) analyzed 411 gliomas of Japanese patients (median age of 46 years (ranged between 1 to 87 years)). Direct sequencing revealed H3F3A p.K27R in one 51 years of age oligodendrogl… (full text at CIViC)

PMID 28447171 · Yoshimoto et al., 2017 · Open in CIViC

Using Sanger sequencing, H3F3A mutations in patients with pediatric low-grade gliomas (PLGGs) were identified (K27M: 13/280; G34R: 5/280). Kaplan-Meier survival analysis showed that H3F3A mutations we… (full text at CIViC)

PMID 29948154 · Yang et al., 2018 · Open in CIViC

Whole exome sequencing was performed on the glioblastomas of 48 patients (between 3 and 20 years of age). The authors also analyzed gliomas of 784 patients of various ages. The G34R/G34V variant has b… (full text at CIViC)

PMID 22286061 · Schwartzentruber et al., 2012 · Open in CIViC

Two adult patients with diffuse midline glioma (DMG) harboring a somatic H3F3B K27I mutation were reported. Next-generation sequencing on postoperative tissue was performed using a 539-gene panel (Si… (full text at CIViC)

Open in CIViC

Molecular characterisation of a series of 62 diffuse midline gliomas, H3 K27-altered, revealed a single case of a novel histone H3 variant - H3C14 (HIST2H3C) p.K28M (K7M). The variant occurred in the … (full text at CIViC)

PMID 26399631 · Castel et al., 2015 · Open in CIViC

Whole-genome sequencing (WGS) was performed on the diffuse intrinsic pontine gliomas (DIPGs) and matched germline DNA of 7 pediatric patients. Targeted sequencing was performed on an additional 43 DIP… (full text at CIViC)

PMID 22286216 · Wu et al., 2012 · Open in CIViC

The recurrent HIST1H3B (now known as H3C2, encoding H3.1) p.K27M mutation was identified in human diffuse intrinsic pontine glioma (DIPG) samples and was associated with a significant global reduction… (full text at CIViC)

PMID 23539183 · Lewis et al., 2013 · Open in CIViC

Mariet et al. identified a somatic H3C4 (HIST1H3D) p.Lys28Met (K27M) mutation in a posterior fossa group A ependymoma (EPN_PFA) from an 8-year-old male. The tumor showed H3 K27M immunoreactivity, loss… (full text at CIViC)

PMID 36104744 · Mariet et al., 2022 · Open in CIViC

The study uses HDAC inhibitors, 4-PB and TSA, have differential effects on growth, differentiation, and apoptosis in glioma cells. The authors perform TUNNEL assay and used immunofluorescence to show … (full text at CIViC)

PMID 18360709 · Svechnikova et al., 2008 · Open in CIViC

Three metastatic glioblastoma cell lines were compared with their parental cell lines with regard to differential gene expression. HGF signalling was among the top pathways identified. Exogenous HFG l… (full text at CIViC)

PMID 22203985 · Xie et al., 2012 · Open in CIViC

Public glioma datasets were analyzed from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus. HOXC10 was seen to be significantly elevated in gliomas compared to non-tumor brain tissues, a… (full text at CIViC)

PMID 30429891 · Tan et al., 2018 · Open in CIViC

In determining the mechanisms of angiogenesis in gliomas, an in-depth preclinical analysis of HOXC10 overexpression in response to a vascular endothelial growth factor A (VEGFA) inhibitor bevacizumab … (full text at CIViC)

PMID 30429891 · Tan et al., 2018 · Open in CIViC

In vivo overexpression of HSP90 was observed in segments of the glioma-containing tissue versus the non-tumor-bearing areas in the forebrain of nude mice implanted with bioluminescent intracranial gli… (full text at CIViC)

PMID 28679777 · Canella et al., 2017 · Open in CIViC

In patients with a glioblastoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients.

PMID 19228619 · Yan et al., 2009 · Open in CIViC

In patients with anaplastic astrocytoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients.

PMID 19228619 · Yan et al., 2009 · Open in CIViC

In an experimental in vitro study, glioma cells expressing IDH1 R132C were associated with sensitivity to AGI-5198 (IC50: 0.16M vs. IC50 > 100.00M), as compared to cells expressing wild-type IDH1. Sen… (full text at CIViC)

PMID 23558169 · Rohle et al., 2013 · Open in CIViC

This phase 3 clinical trial was conducted to assess the progression free survival in patients with IDH-mutant gliomas treated with Vorasidenib, an oral brain-penetrant inhibitor, which showed prelimin… (full text at CIViC)

PMID 37272516 · Mellinghoff et al., 2023 · Open in CIViC

In the 2016 WHO classification for CNS tumors, IDH-mutant glioblastoma is recognized as a distinct entity. Whereas IDH-wildtype glioblastoma constitutes about 90% of cases and correspond to de novo gl… (full text at CIViC)

PMID 27157931 · Louis et al., 2016 · Open in CIViC

In a cohort of 55 paired primary and recurrent astrocytic tumors, IDH1 R132H was detected in 24/35 (68.6%) low-grade astrocytomas by R132H-specific immunohistochemistry. DNA sequencing of informative … (full text at CIViC)

PMID 28928859 · Mu et al., 2017 · Open in CIViC